One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Paving the Way for Long-Term Survival in Non–Small-Cell Lung Cancer
Jordi Remon , MD, PhD1; Lizza E. L. Hendriks , MD, PhD2; and Benjamin Besse , MD, PhD3,4
doi : 10.1200/JCO.21.00760
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2321-2323
Patients With Pediatric Brain Tumor: When Do Their Delays Begin?
Stephen A. Sands , PsyD1
doi : 10.1200/JCO.21.01076
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2324-2326
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer , MBBS, PhD1; Mehmet A. N. ?endur, MD2; Delvys Rodr?guez-Abreu , MD3; Keunchil Park , MD, PhD4; Dae Ho Lee , MD, PhD5; Irfan ?için , MD6; Perran Fulden Yumuk , MD7; Francisco J. Orlandi, MD8; Ticiana A. Leal , MD9; Olivier Molinier , MD10; Nopadol Soparattanapaisarn, MD11; Adrian Langleben, MD12; Raffaele Califano, MD13; Balazs Medgyasszay, MD14; Te-Chun Hsia, MD15; Gregory A. Otterson , MD16; Lu Xu, PhD17; Bilal Piperdi, MD17; Ayman Samkari, MD17; and Martin Reck , MD, PhD18 for the KEYNOTE-598 Investigators
doi : 10.1200/JCO.20.03579
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2327-2338
Pembrolizumab monotherapy is standard first-line therapy for metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ? 50% without actionable driver mutations. It is not known whether adding ipilimumab to pembrolizumab improves efficacy over pembrolizumab alone in this population.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50%
Martin Reck , MD, PhD1; Delvys Rodr?guez-Abreu , MD, PhD2; Andrew G. Robinson , MD, MSc3; Rina Hui, MBBS, PhD4; Tibor Cs?szi, MD5; Andrea Fül?p, MD6; Maya Gottfried, MD7; Nir Peled , MD, PhD8; Ali Tafreshi, MD9; Sinead Cuffe, MD10; Mary O'Brien, MD11; Suman Rao, MD12; Katsuyuki Hotta , MD, PhD, MPH13; Ticiana A. Leal , MD14; Jonathan W. Riess , MD, MS15; Erin Jensen, MS16; Bin Zhao, MD, PhD16; M. Catherine Pietanza, MD16; and Julie R. Brahmer, MD17
doi : 10.1200/JCO.21.00174
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2339-2349
We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients with previously untreated NSCLC with a programmed death ligand-1 (PD-L1) tumor proportion score of at least 50% and no sensitizing EGFR or ALK alterations. Previous analyses showed pembrolizumab significantly improved progression-free survival and overall survival (OS).
Predictors of Cognitive Performance Among Infants Treated for Brain Tumors: Findings From a Multisite, Prospective, Longitudinal Trial
Jeanelle S. Ali, PhD1; Jason M. Ashford, MS1; Michelle A. Swain, PhD2; Lana L. Harder, PhD3; Bonnie L. Carlson-Green, PhD4; Jonathan M. Miller, PhD4; Joanna Wallace, PhD5; Ryan J. Kaner, PsyD6; Catherine A. Billups, MS7; Arzu Onar-Thomas, PhD7; Thomas E. Merchant, DO, PhD8; Amar Gajjar, MD9; and Heather M. Conklin, PhD1
doi : 10.1200/JCO.20.01687
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2350-2358
Infants treated for CNS malignancies experience a significantly poorer response to treatment and are particularly at risk for neuropsychological deficits. The literature is limited and inconsistent regarding cognitive outcomes among this group. We investigated predictors of cognitive outcomes in children treated for brain tumors during infancy as part of a large, prospective, multisite, longitudinal trial.
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J. Wirth , MD1; Marcia S. Brose , MD, PhD2; Eric J. Sherman , MD3; Lisa Licitra , MD4; Martin Schlumberger , MD5; Steven I. Sherman , MD6; Keith C. Bible , MD, PhD7; Bruce Robinson, MD8; Patrice Rodien, MD, PhD9; Yann Godbert, MD10; Christelle De La Fouchardiere , MD11; Kate Newbold, MD12; Christopher Nutting, MD12; Soamnauth Misir, PharmD13; Ran Xie , PharmD14; Ana Almonte, PharmD14; Weifei Ye, PharmD13; and Maria E. Cabanillas , MD6
doi : 10.1200/JCO.20.03093
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2359-2366
Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions. Lenvatinib is US Food and Drug Administration–approved for radioiodine-refractory differentiated thyroid cancer and has previously demonstrated activity in a small study of patients with ATC (n = 17). We aimed to further evaluate lenvatinib in ATC.
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial
Melody A. Cobleigh, MD1,2; Stewart J. Anderson, PhD1,3; Kalliopi P. Siziopikou, MD1,4; Douglas W. Arthur, MD1,5; Rachel Rabinovitch, MD1,6; Thomas B. Julian, MD1,7; David S. Parda, MD1,7; Samantha A. Seaward, MD1,8; Dennis L. Carter, MD9,10; Janice A. Lyons, MD11; Melissa S. Dillmon, MD12; Gustav C. Magrinat, MD1,13; Vivek S. Kavadi, MD1,10; Allison M. Zibelli, MD14; Lavanya Tiriveedhi, MD1,15; Matthew L. Hill, DO1,16; Marianne K. Melnik, MD1,17; Sushil Beriwal, MD1,18; Eleftherios P. Mamounas, MD1,19; and Norman Wolmark, MD1,3
doi : 10.1200/JCO.20.02824
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2367-2374
Preclinical studies report that trastuzumab (T) can boost radiotherapy (RT) effectiveness. The primary aim of the B-43 trial was to assess the efficacy of RT alone vs concurrent RT plus T in preventing recurrence of ipsilateral breast cancer (IBTR) in women with ductal carcinoma in situ (DCIS).
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney, MD, MPH1,2; Nabihah Tayob, PhD1; Chau Dang, MD3; Denise A. Yardley, MD4; Steven J. Isakoff, MD, PhD5; Vicente Valero, MD6; Meredith Faggen, MD1; Therese Mulvey, MD5; Ron Bose, MD, PhD7; Jiani Hu, MSc1; Douglas Weckstein, MD1; Antonio C. Wolff, MD8; Katherine Reeder-Hayes, MD, MBA, MSc9; Hope S. Rugo, MD10; Bhuvaneswari Ramaswamy, MD11; Dan Zuckerman, MD12; Lowell Hart, MD13; Vijayakrishna K. Gadi, MD, PhD14; Michael Constantine, MD1; Kit Cheng, MD15; Frederick Briccetti, MD1; Bryan Schneider, MD16; Audrey Merrill Garrett, MD17; Kelly Marcom, MD18; Kathy Albain, MD19; Patricia DeFusco, MD20; Nadine Tung, MD2,21; Blair Ardman, MD22; Rita Nanda, MD23; Rachel C. Jankowitz, MD24; Mothaffar Rimawi, MD25; Vandana Abramson, MD26; Paula R. Pohlmann, MD, PhD, MSc27; Catherine Van Poznak, MD28; Andres Forero-Torres, MD29; Minetta Liu, MD30; Kathryn Ruddy, MD30; Yue Zheng, MSc1; Shoshana M. Rosenberg, ScD, MPH1,2; Richard D. Gelber, PhD1,2; Lorenzo Trippa, PhD1,2; William Barry, PhD1; Michelle DeMeo, BS1; Harold Burstein, MD, PhD1,2; Ann Partridge, MD, MPH1,2; Eric P. Winer, MD1,2; and Ian Krop, MD, PhD1,2
doi : 10.1200/JCO.20.03398
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2375-2385
The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC).
Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Apar Gupta, MD, MBA1; Sachin R. Jhawar, MD2; Mutlay Sayan, MD3; Zeinab A. Yehia, MD3; Bruce G. Haffty, MD3; James B. Yu, MD4,5; and Shi-Yi Wang, MD, PhD4,6
doi : 10.1200/JCO.21.00831
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2386-2396
Ductal carcinoma in situ (DCIS) accounts for 20% of breast cancer cases in the United States and is potentially overtreated, leading to high expenditures and low-value care. We conducted a cost-effectiveness analysis evaluating all adjuvant treatment strategies for DCIS.
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation
Neema P. Mayor , PhD1,2; Tao Wang, PhD3,4; Stephanie J. Lee , MD, MPH5,6; Michelle Kuxhausen, MS5; Cynthia Vierra-Green, MS5; Dominic J. Barker, MSc1; Jeffrey Auletta, MD7; Vijaya R. Bhatt , MBBS8; Shahinaz M. Gadalla , MD, PhD9; Loren Gragert , PhD10; Yoshihiro Inamoto , MD, PhD11; Gerald P. Morris , MD, PhD12; Sophie Paczesny , MD, PhD13; Ran Reshef , MD14; Olle Ringdén , MD, PhD15; Bronwen E. Shaw , MD, PhD4; Peter Shaw , MD, MA, MBBS16; Stephen R. Spellman , MBS5; and Steven G. E. Marsh , PhD1,2
doi : 10.1200/JCO.20.03643
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2397-2409
Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hematopoietic cell transplantation, improving survival and reducing post-transplant complications. However, most studies included relatively small numbers of patients. Here we report the findings from a large, multicenter validation study.
Confidence
Ash B. Alpert , MD, MFA1 and Bahar Moftakhar , MD1
doi : 10.1200/JCO.21.00012
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2410-2412
Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy
Gege Gui, ScM, Laura W. Dillon , PhD, and Christopher S. Hourigan , DM, DPhil
doi : 10.1200/JCO.21.00255
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2413-2415
Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer
Kazuki Yokoyama, MD and Hiroto Ishiki , MD
doi : 10.1200/JCO.21.00456
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2415-2416
Reply to G. Gui et al
Charles Craddock , MD, Aimee Jackson, BSc, and Sylvie D. Freeman , MD, DPhil
doi : 10.1200/JCO.21.00603
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2416-2417
Reply to K. Yokoyama et al
Christopher W. Noel , MD, Rinku Sutradhar, PhD, Haoyu Zhao, MPH, Victoria Delibasic, BHSc, David Forner , MD, MSc, Jonathan C. Irish, MD, MSc, John Kim, MD, Zain Husain, MD, Alyson Mahar, PhD, Irene Karam, MD, Danny J. Enepekides, MD, MPH, Kelvin K. W. Chan , MD, MSc, PhD, Simron Singh , MD, MPH, Julie Hallet , MD, MSc, Natalie G. Coburn, MD, MPH, and Antoine Eskander , MD, ScM
doi : 10.1200/JCO.21.00688
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2417-2419
Erratum
doi : 10.1200/JCO.21.01441
Journal of Clinical Oncology 39, no. 21 (July 20, 2021) 2420-2420
